KLRA — KAILERA THERAPEUTICS INC
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
As of Q2 2026, 106 SEC-registered investment managers reported holding KLRA (KAILERA THERAPEUTICS INC) in their latest 13F filings, with a combined reported value of $2.69B across 125.49M shares. That is +50.0% by share count (+10.00K shares) versus the previous quarter, while reported value moved +20.0%. Ownership is concentrated: the five largest holders account for 59.1% of reported value and the top ten for 73.8%.
Compared with the prior quarter, 105 opened new positions, 1 added to existing stakes. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.
Major shareholders of KAILERA THERAPEUTICS INC (KLRA) include BAIN CAPITAL INVESTORS LLC, Bain Capital Life Sciences Investors, LLC, RTW INVESTMENTS, LP, ranked by reported 13F value among the 151 institutional holders on this page.
KLRA is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
Institutional Ownership by Quarter
| Quarter | Funds holding | Shares | Value | QoQ Net Change |
|---|---|---|---|---|
| Q3 2026 | 80 | 32.48M | $371.48M | +7.1% |
| Q2 2026 | 106 | 125.49M | $2.69B | +50.0% |
| Q1 2026 | 1 | 20.00K | $26.00K | +0.0% |
| Q4 2025 | 1 | 20.00K | $23.20K | — |
| Q4 2023 | 7 | 142.02K | $44.04M | +139.9% |
| Q3 2023 | 6 | 45.60K | $7.42M | — |
| Q2 2023 | 1 | 130.00K | $28.19M | +983.3% |
| Q1 2023 | 1 | 12.00K | $2.18M | +114.3% |
Over the 8 quarters shown, institutional share counts increased 270558% in aggregate (Q1 2023 → Q3 2026); the largest single-quarter swing was Q2 2023 (+983.3%).
Top Institutional Holders (Q3 2026) — 25 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 5.17M | $59.06M | 9.36% | Hold | |
| 4.66M | $53.22M | 0.00% | Add | |
| 4.57M | $52.22M | 0.00% | Add | |
| 2.46M | $28.04M | 14.29% | Hold | |
| 2.24M | $25.60M | 0.00% | New | |
| 2.21M | $25.29M | 0.60% | Hold | |
| 1.68M | $19.21M | 0.00% | Reduce | |
| 1.62M | $18.50M | 0.00% | Reduce | |
| 1.21M | $13.79M | 0.00% | Add | |
| 878.20K | $10.03M | 0.02% | New | |
| 469.58K | $5.36M | 0.00% | Reduce | |
| 401.44K | $5.14M | 0.00% | Hold | |
| 432.66K | $4.94M | 0.01% | Add | |
| 416.85K | $4.76M | 0.03% | New | |
| 403.69K | $4.61M | 0.01% | Reduce | |
| 381.00K | $4.35M | 0.04% | New | |
| 310.27K | $3.54M | 0.01% | Add | |
| 290.14K | $3.31M | 0.00% | Hold | |
| 260.80K | $2.98M | 0.01% | Add | |
| 198.55K | $2.27M | 0.00% | New | |
| 171.74K | $1.96M | 0.01% | Add | |
| 155.40K | $1.77M | 0.00% | Add | |
| 151.00K | $1.72M | 0.01% | New | |
| 147.19K | $1.68M | 0.00% | Add | |
| 140.93K | $1.61M | 0.00% | Add |
Holder history for earlier quarters, one table per quarter: Back to the Top 25 holders
Q2 2026 — 25 funds
Q1 2026 — 1 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 20.00K | $26.00K | 0.00% | Hold |
Q4 2025 — 1 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 20.00K | $23.20K | 0.00% | New |
Q4 2023 — 7 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 50.10K | $15.86M | 0.02% | Add | |
| 50.00K | $15.83M | 0.00% | New | |
| 24.00K | $7.60M | 0.03% | Add | |
| 12.00K | $3.80M | 0.07% | Add | |
| 1.12K | $353.54K | 0.05% | Reduce | |
| 1.00K | $316.51K | 0.03% | New | |
| 3.80K | $292.79K | 0.20% | New |
Q3 2023 — 6 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 22.40K | $3.79M | 0.01% | New | |
| 7.50K | $1.27M | 0.01% | New | |
| 6.70K | $1.13M | 0.01% | New | |
| 4.90K | $828.54K | 0.02% | New | |
| 2.35K | $397.19K | 0.06% | New | |
| 1.75K | $4.21K | 0.00% | New |
New Positions (Q2 2026)
- BAIN CAPITAL INVESTORS LLC 26.26M sh · $578.41M
- Bain Capital Life Sciences Investors, LLC 22.58M sh · $497.51M
- RTW INVESTMENTS, LP 10.78M sh · $237.41M
- CPP Investments 7.30M sh · $160.92M
- Atlas Venture Life Science Advisors, LLC 5.17M sh · $113.92M
- Fidelity Management & Research (FMR) 3.97M sh · $87.48M
- BlackRock Inc 3.93M sh · $86.55M
- PRICE T ROWE ASSOCIATES INC /MD/ 3.53M sh · $77.86M
- Citadel Advisors 3.24M sh · $71.39M
- ADAGE CAPITAL PARTNERS GP, L.L.C. 3.21M sh · $70.68M
- Wellington Management Group 2.92M sh · $64.31M
- WELLINGTON MANAGEMENT GROUP LLP 2.92M sh · $64.31M
Fully Exited (vs previous quarter)
No tracked fund fully exited this quarter.
Fund Position History — shares by quarter (top 20 funds)
| Fund | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC | 5.17M | 5.17M | — | — | — | — | — | — | — | — |
| Fidelity Management & Research (FMR) | 4.66M | 3.97M | — | — | — | — | — | — | — | — |
| BlackRock Inc | 4.57M | 3.93M | — | — | — | — | — | — | — | — |
| Royalty Pharma Sub-Manager, LLC | 2.46M | 2.46M | — | — | — | — | — | — | — | — |
| STATE STREET CORP | 2.24M | — | — | — | — | — | — | — | — | — |
| Siren, L.L.C. | 2.21M | 2.21M | — | — | — | — | — | — | — | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.68M | 1.69M | — | — | — | — | — | — | — | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.62M | 1.65M | — | — | — | — | — | — | — | — |
| Geode Capital Management | 1.21M | 1.13M | — | — | — | — | — | — | — | — |
| Marshall Wace | 878.20K | — | — | — | — | — | — | — | — | — |
| UBS Group AG | 469.58K | 972.68K | — | — | — | — | — | — | — | — |
| Franklin Resources | 401.44K | 400.02K | — | — | — | — | — | — | — | — |
| Aberdeen Group plc | 432.66K | 140.00K | — | — | — | — | — | — | — | — |
| Walleye Capital LLC | 416.85K | — | — | — | — | — | — | — | — | — |
| FEDERATED HERMES, INC. | 403.69K | 434.07K | — | — | — | — | — | — | — | — |
| Jump Financial, LLC | 381.00K | — | — | — | — | — | — | — | — | — |
| BNP PARIBAS FINANCIAL MARKETS | 310.27K | 7.00K | — | — | — | — | — | — | — | — |
| VANGUARD FIDUCIARY TRUST CO | 290.14K | 290.13K | — | — | — | — | — | — | — | — |
| EXCHANGE TRADED CONCEPTS, LLC | 260.80K | 152.50K | — | — | — | — | — | — | — | — |
| Renaissance Technologies | 198.55K | — | — | — | — | — | — | — | — | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details
FAQ
Which funds hold KLRA?
As of 2026-Q2, 106 institutional funds reported holding KLRA (KAILERA THERAPEUTICS INC) in SEC 13F filings, with a combined reported value of $2.69B.
How many shares of KLRA do institutions own?
13F filers reported 125.49M shares of KLRA, worth $2.69B in aggregate at the end of 2026-Q2.
Is institutional ownership of KLRA rising or falling?
Share counts moved +50.0% versus the prior quarter — accumulation.
Who are the top institutional holders of KLRA?
The largest 13F holders are BAIN CAPITAL INVESTORS LLC, Bain Capital Life Sciences Investors, LLC, RTW INVESTMENTS, LP, CPP Investments, PRICE T ROWE ASSOCIATES INC /MD/; the top 25 are ranked at the top of this page.
Who are the major shareholders of KAILERA THERAPEUTICS INC?
The major shareholders of KAILERA THERAPEUTICS INC (KLRA) by reported 13F value are BAIN CAPITAL INVESTORS LLC, Bain Capital Life Sciences Investors, LLC, RTW INVESTMENTS, LP, CPP Investments, PRICE T ROWE ASSOCIATES INC /MD/, among 151 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.